Biosimilar Clinical Development: Scientific Considerations and New Methodologies (Chapman & Hall/CRC Biostatistics Series) - Hardcover

Hardcover

ISBN 10: 1482231697 ISBN 13: 9781482231694

Publisher: Chapman and Hall/CRC, 2017

Synopsis

Biosimilars have the potential to change the way we think about, identify, and manage health problems. They are already impacting both clinical research and patient care, and this impact will only grow as our understanding and technologies improve. Written by a team of experienced specialists in clinical development, this book discusses various potential drug development strategies, the design and analysis of pharmacokinetics (PK) studies, and the design and analysis of efficacy studies.

About this title

About the Author

Dr. Kerry B. Barker is the Vice-President and Head of Early Oncology Research Statistics at Pfizer, Dr. Sandeep Menon is the Vice-President and Head of Biostatistics Research and Consulting Center at Pfizer , Dr. Ralph D’Agostino is a professor of Mathematics and Statistics at Boston University, Dr. Siyan Xu is a senior principal biostatistician at Novartis and Dr.Bo Jin is the Director of Biostatistics in Early Oncology Research at Pfizer. All have been involved with biosimilars clinical development across all regions of the world.

Edition details

• Publisher: Chapman and Hall/CRC
• Publication date: 2017
• Language: English
• ISBN 10: 1482231697
• ISBN 13: 9781482231694
• Binding: Hardcover
• Edition number: 1
• Number of pages: 248
• Editor: Barker Kerry B., Menon Sandeep M., D'Agostino Sr. Ralph B., Xu Siyan, Jin PhD Bo